Why the study?
What is the prevalence of human parechovirus and human herpes virus-6 in the cerebrospinal fluid of infants tested for enterovirus or herpes simplex virus?
What is the prevalence of human parechovirus and human herpes virus-6 in the cerebrospinal fluid of infants tested for enterovirus or herpes simplex virus?
Five percent of infants under 6 months tested for EV or HSV have HPeV or HHV-6 in their CSF, suggesting targeted testing may increase diagnostic yield.
Answers are grounded in this paper and cite their sources.
May support targeted testing to increase diagnostic yield in young infants; hypothesis-generating pending prospective validation.
Human parechovirus (HPeV) and human herpes virus-6 (HHV-6) are acquired commonly in infancy and associated with central nervous system infection. The prevalence of HPeV and HHV-6 in the cerebrospinal fluid (CSF) of infants tested for enterovirus (EV) and herpes-simplex virus (HSV) is unknown. All stored CSF samples from EV or HSV testing in infants less than 6 months of age at Children's Hospital Colorado between January 1, 2010 and December 31, 2011 were tested for HPeV, HHV-6, EV, and HSV by PCR. Clinical characteristics and epidemiological data were collected using retrospective electronic chart review. Of 239 infants tested, 29 cases of EV (12.1%), 7 cases of HPeV (2.9%), 5 cases of HHV-6 (2.1%), and 5 cases of HSV (2.1%) were identified with no bacterial co-infections. HPeV cases occurred between July and October in infants with median age of 24 days. Infants with HPeV had a median maximum temperature of 39 °C, median fever duration of 3 days and median peripheral white blood cell count of 5.2 × 10(3)/μL. HHV-6 cases occurred in infants with median age of 61 days without seasonality. Five percent of infants less than 6 months of age undergoing testing for EV or HSV have HPeV or HHV-6 in the CSF. Targeting testing of HPeV towards febrile infants less than 2 months of age with leukopenia in the late summer to early fall, and HHV-6 towards older infants may increase diagnostic yield. The clinical and fiscal impact of testing infants for HPeV and HHV-6 needs to be determined.
No takes yet. Share an insight, caveat, or question.
Messacar et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: